Acute Myocardial InfarctionMSC-AMINCT04104269
Mechanical Structure Complications After Acute Myocardial Infarction
An observational study of Acute Myocardial Infarction, run by Xiamen Cardiovascular Hospital, Xiamen University at 1 site in China.
Trial summary
To determine the incidence and factors associated with heart rupture (HR) in acute myocardial infarction patients. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Myocardial Infarction
- What is being tested?
- Heart rupture
- How many people
- 35,621 participants
- Where
- 1 siteChina
- Study dates
- 1 Jan 2011to 31 Jan 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population of acute myocardial infarction (STEMI or NSTEMI) patients.
Who may be able to join
- 1. Patients be admitted for acute myocardial infarction (STEMI or NSTEMI)
Who cannot join
- 1. Non-cardiovascular comorbidity for AMI
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
Xiamen Cardiovascular Hospital Xiamen University
Xiamen, Fujian, 361000
Xile Bi, Dr., 150930593145, bixile@163.com
About this study
Official title: Comparative Risk Factors of Mechanical Structure Complications After Acute Myocardial Infarction
To determine the incidence and factors associated with heart rupture (HR) in acute myocardial infarction patients.
Read the detailed description
We compared characteristics and angiographic patterns of heart rupture and without heart rupture patients enrolled in the trial.
- Conditions
- Acute Myocardial Infarction
- Being tested
- Heart rupture
- Keywords
- Heart rupture, Acute myocardial infarction
- Medical subject headings
- Heart Rupture
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Heart ruptureDiagnostic test
Free wall rupture and Ventricular septal rupture
| Study group | Role | What they receive |
|---|---|---|
| Mechanical Complications | Include free wall ventricular rupture and ventricular septal rupture Receives: Diagnostic Test: Heart rupture | |
| Non-Mechanical Complications | Mechanical complications were not included in patients with AMI |
What is being measured
The primary outcome is the main question the study is designed to answer.
Heart rupture
Includee free wall ventricular rupture and ventricular septal rupture
Measured: Mortality 30 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Sep 2019
- Study start1 Jan 2011
- Primary completion31 Dec 2019 (estimated)
- Study completion31 Jan 2020 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Myocardial InfarctionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 35,621 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Xiamen Cardiovascular Hospital, Xiamen University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Yan Wang, Xiamen Cardiovascular Hospital, Xiamen University
- Investigators
- Yan Wang, PhD, Study chair, Xiamen Cardiovascular Hospital, Xiamen University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04104269
- Sponsor's protocol ID
- 9215443687
- Acronym
- MSC-AMI
- Status last verified
- Nov 2019
- First submitted
- 24 Sep 2019
- Last updated
- 26 Nov 2019
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Nov 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparative Risk Factors of Mechanical Structure Complications After Acute Myocardial Infarction
- ClinicalTrials.gov ID
- NCT04104269
- Acronym / sponsor ID
- MSC-AMI / 9215443687
- Conditions
- Acute Myocardial Infarction
- Keywords
- Heart rupture, Acute myocardial infarction
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 35,621 participants (estimated)
- Lead sponsor
- Xiamen Cardiovascular Hospital, Xiamen UniversityUniversity, hospital or other
- Study start
- 1 Jan 2011 (actual)
- Primary completion
- 31 Dec 2019 (estimated)
- Study completion
- 31 Jan 2020 (estimated)
- First posted
- 26 Sep 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To determine the incidence and factors associated with heart rupture (HR) in acute myocardial infarction patients.
Detailed description
We compared characteristics and angiographic patterns of heart rupture and without heart rupture patients enrolled in the trial.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Mechanical Complications | – | Diagnostic Test: Heart ruptureInclude free wall ventricular rupture and ventricular septal rupture |
| Non-Mechanical Complications | – | –Mechanical complications were not included in patients with AMI |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population of acute myocardial infarction (STEMI or NSTEMI) patients.
Key inclusion criteria (1 listed)
- 1. Patients be admitted for acute myocardial infarction (STEMI or NSTEMI)
Key exclusion criteria (1 listed)
- 1. Non-cardiovascular comorbidity for AMI
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Heart ruptureFree wall rupture and Ventricular septal rupture | Diagnostic test | Mechanical Complications |
Primary outcome
Heart rupture
Time frame: Mortality 30 days
Includee free wall ventricular rupture and ventricular septal rupture
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Nov 2019.
- Individual participant dataSharing planned: No
Related trials for Acute Myocardial Infarction
Recruiting
Heart@Home Safety and Efficacy of Hospital-at-Home Care Versus Standard Hospitalization in Cardiac Patients
Myocardial Infarction, Myocarditis Acute
Enrolling by invitationPhase 3
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
Acute Myocardial Infarction
RecruitingObservational study
Assessment of Support With Impella® Best Practices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
AMI Cardiogenic Shock
RecruitingObservational study
Cardiogenic Shock Working Group Registry
Cardiogenic Shock
Recruiting
CRP Apheresis in Infarct-Related Cardiogenic Shock
Cardiogenic Shock, Acute Myocardial Infarction (AMI)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Yan Wang, PhD study chair
Xiamen Cardiovascular Hospital, Xiamen University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Myocardial Infarction, run by Xiamen Cardiovascular Hospital, Xiamen University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 26 Nov 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Yan Wang, PhD (8613860488088, wy@medmail.com.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Heart rupture (time frame: Mortality 30 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Nov 2019.